Eloxx Pharmaceuticals, Inc. (ELOX): Total Assets
$5.27M
As of 2025-12-31
$63.39M
As of 2026-06-30
-37.0%
3-year compound annual growth
-27.6%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $5.27M | +77.1% | 2026-03-17, Balance as of period end |
| 2024-12-31 | $2.98M | +73.8% | 2026-03-17, Balance as of period end |
| 2023-12-31 | $1.71M | -91.9% | 2026-03-17, Balance as of period end |
| 2022-12-31 | $21.12M | -53.2% | 2023-03-31, Balance as of period end |
| 2021-12-31 | $45.14M | +70.5% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $26.48M | -55.1% | 2022-03-30, Balance as of period end |
| 2019-12-31 | $58.95M | +16.2% | 2021-03-12, Balance as of period end |
| 2018-12-31 | $50.72M | +104.6% | 2020-03-06, Balance as of period end |
| 2017-12-31 | $24.78M | n/a | 2019-03-14, Balance as of period end |
| 2017-06-30 | $5.85M | n/a | 2017-10-13, Balance as of period end |
| 2016-12-31 | $3.13M | n/a | 2018-03-16, Balance as of period end |
| 2016-06-30 | $9.23M | -52.8% | 2017-10-13, Balance as of period end |
| 2015-06-30 | $19.55M | -41.4% | 2016-10-13, Balance as of period end |
| 2014-06-30 | $33.33M | +369.7% | 2015-10-09, Balance as of period end |
| 2013-06-30 | $7.10M | +2.1% | 2014-09-29, Balance as of period end |
| 2012-06-30 | $6.95M | -19.1% | 2013-09-11, Balance as of period end |
| 2011-06-30 | $8.60M | n/a | 2012-10-26, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc. (ELOX) | 2025-12-31 | $5.27M | +77.1% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $186.08M | +11.8% |
| Amgen Inc (AMGN) | 2025-12-31 | $90.59B | -1.4% |
| Repligen Corp (RGEN) | 2025-12-31 | $2.95B | +4.2% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $26.99M | -16.6% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $2.59B | +1.1% |
| Biogen Inc. (BIIB) | 2025-12-31 | $29.44B | +5.0% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $112.58M | -0.6% |
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $59.02B | 0.0% |
Compare ELOX, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗